Advertisement

Douleur et Analgésie

, Volume 30, Issue 4, pp 239–249 | Cite as

Efficacité et tolérance des capsaïcinoïdes topiques dans le traitement de la douleur neuropathique. Une revue systématique et méta-analyse des essais cliniques randomisés

  • A. U. Trillig
  • R. Deumens
  • A. Mouraux
  • F. Bauchy
  • P. Forget
Article Original / Original Article

Résumé

Introduction

La douleur neuropathique est fréquente, et sa prise en charge peut être difficile en cas d’inefficacité des traitements et de survenue d’effets secondaires. Une alternative aux traitements systémiques est l’application topique de capsaïcinoïdes. L’objectif du travail est d’évaluer l’efficacité d’un traitement topique à base de capsaïcinoïdes dans le traitement de la douleur neuropathique.

Méthodes

En accord avec les recommandations PRISMA, une recherche systématique des essais cliniques publiés entre le 1er janvier 1990 et le 31 août 2014, en langue anglaise et française, a été réalisée dans PubMed/Central et la Cochrane Database. Les indications, les modalités de traitement et les résultats thérapeutiques ont été collectés. Des analyses qualitative et quantitative (méta-analyses) des données ont été réalisées.

Résultats

Dix-sept études ont été incluses à partir de 153 études identifiées. Les données rassemblées permettent de conclure à l’efficacité de la capsaïcine pour traiter les douleurs neuropathiques postherpétiques et la polyneuropathie sensorielle distale associée au VIH. Les indications pourraient être élargies, mais les données sont insuffisantes pour tirer des conclusions.

Conclusion

La capsaïcine topique est efficace pour les douleurs neuropathiques postherpétiques et dans la neuropathie associée au VIH. Des recherches complémentaires sont nécessaires dans d’autres indications, ainsi que pour évaluer l’éventuelle place d’autres capsaïcinoïdes.

Mots clés

Capsaïcine Capsaïcinoïdes Douleur neuropathique 

Efficacy and tolerance of topical capsaicinoids in the treatment of neuropathic pain. a systematic review and meta-analysis of randomized controlled trials

Abstract

Introduction

Neuropathic pain is frequent and its management can be difficult in case of unsuccessful treatment and side effects. An alternative to systemic treatments is the topical use of capsaicinoids. The goal of this work is to evaluate the efficacy of the topical use of capsaicinoids to treat neuropathic pain.

Method

In agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a systematic research of clinical trials published between 1/1/1990 and 31/08/2014, in English and French, was performed in PubMed/Central and the Cochrane Database. The indications, modalities of treatment and therapeutic results were registered. Qualitative and quantitative (meta-) analyses of the data were performed.

Results

Seventeen studies were included, from 153 identified works. The extracted data permitted us to conclude that capsaicin is efficient in treating post-herpetic neuropathic pain as distal HIV-associated polyneuropathy. The data are insufficient to conclude whether the indications may be broadened.

Conclusion

Topical capsaicin is effective in treating postherpetic and HIV-associated neuropathic pain. Further studies are needed to evaluate other indications and the potential place of other capsaicinoids.

Keywords

Capsaicine Capsaicinoids Neuropathic pain 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Van Hecke O, Austin SK, Khan RA, et al (2014) Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 155:654–62CrossRefPubMedGoogle Scholar
  2. 2.
    Maihofner C, Heskamp ML (2013) Prospective, noninterventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1,044 patients with peripheral neuropathic pain: first results of the QUEPP Study. Curr Med Res Opin 29:673–83CrossRefPubMedGoogle Scholar
  3. 3.
    Backonja MM, Malan TP, Vanhove GF, et al (2010) NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension. Pain Med 11:600–8CrossRefPubMedGoogle Scholar
  4. 4.
    Wagner T, Poole C, Roth-Daniek A (2013) The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis. Pain Med 14:1202–11CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Webster LR, Peppin JF, Murphy FT, et al (2011) Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an openlabel study of patients with peripheral neuropathic pain. Diabetes Res Clin Pract 93:187–97CrossRefPubMedGoogle Scholar
  6. 6.
    Irving GA, Backonja MM, Dunteman E, et al (2011) A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med 12:99–109CrossRefPubMedGoogle Scholar
  7. 7.
    Peikert A, Hentrich M, Ochs G (1991) Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course. J Neurol 238:452–6CrossRefPubMedGoogle Scholar
  8. 8.
    Ribbers GM, Stam HJ (2001) Complex regional pain syndrome type I treated with topical capsaicin: a case report. Arch Phys Med Rehabil 82:851–2CrossRefPubMedGoogle Scholar
  9. 9.
    Derry S, Sven-Rice A, Cole P, et al (2013) Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2: CD007393.Google Scholar
  10. 10.
    Olivo SA, Macedo LG, Gadotti IC, et al (2008) Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther 88:156–75CrossRefPubMedGoogle Scholar
  11. 11.
    Webster LR, Tark M, Rauck R, et al (2010) Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. BMC Neurol 10:92CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Webster LR, Malan TP, Tuchman MM, et al (2010) A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. J Pain 11:972–82CrossRefPubMedGoogle Scholar
  13. 13.
    Backonja M, Wallace MS, Blonsky ER, et al (2008) NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol 7:1106–12CrossRefPubMedGoogle Scholar
  14. 14.
    Watson CP, Tyler KL, Bickers DR, et al (1993) A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 15:510–26PubMedGoogle Scholar
  15. 15.
    Kulkantrakorn K, Lorsuwansiri C, Meesawatsom P (2013) 0.025% capsaicin gel for the treatment of painful diabetic neuropathy: a randomized, double-blind, crossover, placebo-controlled trial. Pain Pract 13:497–503CrossRefPubMedGoogle Scholar
  16. 16.
    Low PA, Opfer-Gehrking TL, Dyck PJ, et al (1995) Doubleblind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain 62:163CrossRefPubMedGoogle Scholar
  17. 17.
    Clifford DB, Simpson DM, Brown S, et al (2012) A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr 59:126–33CrossRefPubMedGoogle Scholar
  18. 18.
    Simpson DM, Brown S, Tobias J, NGX-4010 C107 Study Group (2008) Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 70:2305–13CrossRefPubMedGoogle Scholar
  19. 19.
    Simpson DM, Gazda S, Brown S, et al (2010) Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain. J Pain Symptom Manage 39:1053–64CrossRefPubMedGoogle Scholar
  20. 20.
    Fusco BM, Alessandri M (1992) Analgesic effect of capsaicin in idiopathic trigeminal neuralgia. Anesth Analg 74:375–7CrossRefPubMedGoogle Scholar
  21. 21.
    Frucht-Pery J, Feldman ST, Brown SI (1997) The use of capsaicin in herpes zoster ophthalmicus neuralgia. Acta Ophthalmol Scand 75:311–3CrossRefPubMedGoogle Scholar
  22. 22.
    Sayanlar J, Guleyupoglu N, Portenoy R, Ashina S (2012) Trigeminal postherpetic neuralgia responsive to treatment with capsaicin 8% topical patch: a case report. J Headache Pain 13:587–9CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Perkins P, Morgan S, Closs SP (2003) Topical capsaicin for saphenous neuralgia. J Pain Symptom Manage 26:785–6CrossRefPubMedGoogle Scholar
  24. 24.
    Williams SR, Clark RF, Dunford JV (1995) Contact dermatitis associated with capsaicin: hunan hand syndrome. Ann Emerg Med 25:713–5CrossRefPubMedGoogle Scholar
  25. 25.
    Martini CH, Yassen A, Krebs-Brown A, et al (2013) A novel approach to identify responder subgroups and predictors of response to low- and high-dose capsaicin patches in postherpetic neuralgia. Eur J Pain 17:1491–501PubMedGoogle Scholar
  26. 26.
    A Liberati, Altman DG, Tetzlaff J, et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    U.S. Securities and Exchange Commission. http://www.sec.gov/Archives/edgar/data/1385830/000119312509134470/dex991.htmGoogle Scholar
  28. 28.
    Derry S, Moore RA (2012) Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 9:CD010111Google Scholar
  29. 29.
    Macintyre PE, Schug SA, Scott DA, et al (2010) Acute Pain Management: Scientific Evidence (3rd edition), ANZCA & FPM, MelbourneGoogle Scholar
  30. 30.
    Gärtner R, Jensen MB, Nielsen J, et al (2009) Prevalence of and factors associated with persistent pain following breast cancer surgery. JAMA 302:1985–92CrossRefPubMedGoogle Scholar
  31. 31.
    Jenkins JT, O’Dwyer PJ (2008) Inguinal hernias. BMJ 336:269–72CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Lavoisier 2017

Authors and Affiliations

  • A. U. Trillig
    • 1
  • R. Deumens
    • 2
  • A. Mouraux
    • 2
  • F. Bauchy
    • 1
  • P. Forget
    • 1
    • 2
    • 3
  1. 1.Service d’anesthésiologiecliniques universitaires Saint-LucBruxellesBelgique
  2. 2.Institute of Neuroscienceuniversité catholique de LouvainBruxellesBelgique
  3. 3.Vrije Universiteit Belgium (VUB)Universitair Ziekenhuis Brussel (UZ Brussel), Anesthesiology and Perioperative MedicineBruxellesBelgique

Personalised recommendations